上海莱士 (002252)

Shanghai RAAS Blood Products Co.,Ltd.

ASZ

Tags

300ESG Index300 Non-Cyclical IndexMSCI Mid Cap IndexSpecial Purpose LoansCSI 100 IndexCSI 200 IndexCSI A100 IndexBroker Heavy PositionsGuozheng Growth IndexBiological ProductsEquity TransferIndustry LeadersNon-Cyclical StocksShenzhen ConnectSZSE 100 IndexSZSE 300 IndexSZSE Growth IndexPharma & BiotechConsumer Services IndexSME Board Emerging IndexSZSE Medicine Equal Weight IndexSZSE 100 Equal Weight IndexZhongchuang Equal Weight IndexSina 100 IndexShenzhen A-Share Pharmaceutical IndexBOC International CSI 300 ESG IndexCSI 100 Low Volatility IndexCSI All-share Pharmaceutical Sector IndexSZSE Emerging Industries IndexZhongchuang Growth IndexSZSE 1000 IndexHangzhou Bay Area IndexSME Board Equal Weight IndexSZSE 300 Return IndexCSSW Health IndexCSI 1000 Growth IndexSZSE Component Index ReturnCSI 300 Equal Weight IndexLarge & Mid-cap IndexCNI 1000 IndexXingyin Wealth Management Balanced 300 IndexBiomedicine IndexCR Foundation IndexSME Board Value IndexZhongchuang Value IndexRestructuringMilitary PartsCOVID-19 TestingYangtze River Delta Economic ZoneHuijin ConceptShareholding Increase CommitmentCSI 300 Non-cyclical IndexPension Industry IndexSME Board Composite IndexSZSE Selected IndexTechnology 50 Strategy IndexCS High-end Manufacturing IndexCSI 300 Shenzhen Market IndexZhongchuang 100 Return IndexEmerging Industries Composite IndexSZSE 100 Return IndexManufacturing IndexCSI 300 Growth IndexSZSE Pharmaceutical IndexCSI 800 IndexCS Pharmaceutical TI Index100 Performance IndexCSI 300 Preferred IndexCNI Pharmaceutical IndexCSI 1000 Pharmaceutical IndexCNI 300 IndexCCTV 500 IndexCSI 300 USD (CNH) IndexSZSE Private Enterprises IndexSZSE Component Pharmaceutical IndexPharmaceutical Sub-sector IndexSZSE Low Volatility IndexCSI All-share Pharmaceutical IndexCSI 300 USD IndexSZSE Pharmaceutical 50 IndexSmart Select 300 ESG Leading IndexSME Board Low Volatility IndexSZSE 300 Equal Weight IndexCSI Pharmaceutical IndexCSI 800 Pharmaceutical IndexSZSE Component Index Equal WeightCS Biomedicine IndexCSI 300 Value Stable IndexCSI 300 Pharmaceutical IndexSME Board Performance IndexCSI 700 IndexAH Economic Blue-chip IndexMid-small Cap IndexSZSE Fundamental 200 IndexZhongchuang Low Volatility IndexPharmaceutical 50 Strategy IndexCSI Life Sciences IndexSZSE 200 Return IndexSZSE 200 IndexYangtze River 100 IndexMid-cap Low Volatility IndexCR New Momentum IndexChina Economic Index GDPJuchao Mid-cap IndexCSI 1000 Value IndexFundamental 600 IndexCSI 300 Growth Innovation IndexCS Yangtze River Delta IndexStrategic Emerging Industries 100 IndexShanghai

K-Line Chart

No K-line data available

Company NameShanghai RAAS Blood Products Co., Ltd.
Listing Date2008-06-23
Issue Price12.81RMB
Registered Capital663798.483710k RMB
Legal RepresentativeXu Jun
Registered AddressNo. 2009, Wangyuan Road, Fengxian District, Shanghai
IndustryBiological Products
Main BusinessResearch, development, production, and sales of blood products.
Company ProfileShanghai RAAS Blood Products Co., Ltd. was founded in 1988 and listed on the SME Board of the Shenzhen Stock Exchange in 2008 (Stock Code: 002252). It is a well-known blood products enterprise in Asia. Over the past 30 years since its establishment, the company has consistently adhered to the quality policy of 'Safety, Quality, and Efficiency,' developing a portfolio of 11 products covering three categories of blood products: human albumin, human immunoglobulins, and coagulation factors. Its main products include Human Albumin, Human Immunoglobulin, Intravenous Human Immunoglobulin, Hepatitis B Human Immunoglobulin, Tetanus Human Immunoglobulin, Rabies Human Immunoglobulin, Human Prothrombin Complex, Human Coagulation Factor VIII, Lyophilized Human Thrombin, Human Fibrinogen, and Topical Lyophilized Human Fibrin Sealant. Shanghai RAAS has been registered in nearly 20 countries and is one of the few domestic manufacturers capable of exporting blood products. To date, Shanghai RAAS operates a total of 41 plasma collection stations nationwide (including those under construction), with an annual plasma processing capacity of 900 tons. It has cumulatively sold over 30 million bottles of various blood products, with no confirmed reports of viral infections or product quality-related adverse events.

Stock Details

1. Key Indicators

  • Total Shares(W): 663798.48
  • Circulating A-Shares(W): 663448.96
  • Earnings Per Share(RMB): 0.2220
  • Net Assets Per Share(RMB): 4.9087
  • Operating Revenue(W RMB): 609105.66
  • Total Profit(W RMB): 172372.25
  • Net Profit Attributable to Parent(W RMB): 147073.90
  • Net Profit Growth Rate(%): -19.97
  • Weighted Return on Equity(%): 4.5500
  • Operating Cash Flow Per Share(RMB): 0.1040
  • Undistributed Profit Per Share(RMB): 1.6835
  • Capital Reserve Per Share(RMB): 2.1146

2. Main Business

The main business covers:

  • Production and sales of blood products

3. Company Basic Information

  • Company Name: Shanghai RAAS Blood Products Co., Ltd.
  • Listing Date: 2008-06-23
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 2009 Wangyuan Road, Fengxian District, Shanghai, China
  • Website: www.raas-corp.com
  • Company Profile: The company is a foreign-invested joint-stock company established through the overall transformation of Shanghai RAAS Blood Products Co., Ltd., approved by the Ministry of Commerce of the People's Republic of China (Document No. Shang Zi Pi [2007] No. 17). It obtained the "Approval Certificate for Enterprises with Investment from Taiwan, Hong Kong, Macao and Overseas Chinese" (No. Shang Wai Zi Zi Shen A Zi [2007] No. 0006) on January 18, 2007. The company obtained its amended Business License on March 1, 2007.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Haiyingkang (Qingdao) Medical Technology Co., Ltd. General Legal Person 154751.34 23.33
2 GRIFOLS,S.A. General Legal Person 43706.97 6.59
3 China CITIC Financial Asset Management Co., Ltd. General Legal Person 31411.84 4.73
4 China Cinda Asset Management Co., Ltd. General Legal Person 27920.67 4.21
5 Huabao Trust Co., Ltd. - Huabao-CITIC No.1 Single Fund Trust Asset Management Plan 26809.00 4.04
6 RAAS CHINA LIMITED General Legal Person 15384.91 2.32
7 Huaxin International Trust Co., Ltd. - Huaxin Trust · Wealth Growth Phase V Single Fund Trust Asset Management Plan 13970.00 2.11
8 CITIC Securities Co., Ltd. Broker 12439.27 1.87
9 Hong Kong Securities Clearing Company Ltd. Northbound Capital 9932.04 1.50
10 Huatai-PineBridge CSI 300 Exchange Traded Fund Fund 9036.87 1.36

5. Concept Sectors

  • Innovative Drugs
  • Synthetic Biology
  • Margin Trading & Securities Lending
  • Heavily Held by Brokers
  • Industry Leader
  • MSCI Mid Cap
  • Non-Cyclical Stocks
  • Special Loans
  • CSI 100
  • CSI SME 100
  • SZSE SME 100
  • Mid Cap Growth
  • SZSE 100
  • SZSE 300
  • SZSE Growth
  • SZSE Growth Index
  • CSI 300
  • CSI SME 300
  • CSI 200
  • CSI 300 Non-Cyclical
  • CSI 300 ESG
  • SZSE 50
  • CSI A100

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information